ArticleEuropean radiology2026
Longitudinal wash-in slope changes on dynamic contrast enhancement MRI for predicting response to neoadjuvant chemotherapy in breast cancer.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
objectivesTo determine whether wash-in slope (WIS) changes can predict pathologic complete response (pCR) following NAC in breast cancer. MATERIALS AND
methodsThis single-center retrospective study included consecutive females with breast cancer who received NAC followed by surgery between January 2016 and December 2022. All patients received dynamic contrast-enhanced MRI (DCE-MRI) pretreatment, after 2 cycles, 4 cycles, and after completion of treatment. The percentage change in tumor WIS from that before treatment (ΔWIS) was measured at each time point. Predictive performance for pCR was assessed by using the area under the receiver operating characteristic curve (AUC) for the overall cohort and across molecular subtypes.
resultsA total of 162 patients were included in this study (mean age, 51.9 years ± 9.1 [SD]), and 43 (26.5%) achieved pCR. Overall, ΔWIS demonstrated comparable performance in predicting pCR after 2 cycles (AUC, 0.82; 95% CI: 0.73, 0.91), 4 cycles (AUC, 0.86; 95% CI: 0.78, 0.93), and after completion of NAC (AUC, 0.87; 95% CI: 0.8, 0.93), with no significant differences observed (all p > 0.05). Utilizing optimal threshold values of -33%, -44%, and -59% at each time point, ΔWIS yielded sensitivities ranging from 74.4% to 86.0% and specificities ranging from 75.6% to 80.7%. In molecular subtype analysis, ΔWIS after 4 cycles exhibited excellent predictive performance for pCR in triple-negative breast cancers (AUC, 0.96; 95% CI: 0.9, 1), outperforming its performance in Luminal B tumors (AUC, 0.83; 95% CI: 0.71, 0.94; p = 0.04).
conclusionTumor WIS changes from DCE-MRI could dynamically monitor neoadjuvant chemotherapy (NAC). KEY POINTS: Question Currently, there is no widely accepted standard imaging biomarker for predicting pCR in breast cancer patients undergoing NAC. Findings WIS changes outperformed tumor size in predicting pCR at four time points during NAC, and showed comparable predictive performance across all time points. Clinical relevance Longitudinal changes in the WIS derived from dynamic contrast-enhanced MRI enable real-time prediction of pathologic response to NAC in patients with breast cancer, supporting personalized treatment monitoring and decision-making.
Indexed as
Identifiers
41042372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.